by Barry101 | Nov 15, 2019 | Press Release, Uncategorized
This press release replaces the press release issued 11/15/2019 at 6:30 a.m., which included an incorrect date. The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not December 31, 2019. OCALA, FL / November 15, 2019...
by Barry101 | Nov 15, 2019 | Press Release, Uncategorized
OCALA, FL / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as severe chronic fatigue syndrome (CFS)...
by Barry101 | Oct 23, 2019 | Press Release, Uncategorized
OCALA, FL / October 23, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced that it will be presenting at the Dawson James Securities 5th...
by Barry101 | Oct 7, 2019 | Press Release, Uncategorized
Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA, FL / October 7, 2019 / AIM ImmunoTech Inc. (NYSE American:...
by Barry101 | Sep 25, 2019 | Press Release, Uncategorized
OCALA, FL / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE American:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced the pricing of an underwritten...
by Barry101 | Sep 24, 2019 | Press Release, Uncategorized
New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn ‘Breakthrough Award’ OCALA, FL / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat...
